The global head and neck cancer (HNC) therapeutics market is anticipated to surpass a remarkable worth of US$ 1.58 Billion in 2023, is expected to surpass an impressive valuation of US$ 5.19 Billion by 2033 with a compound annual growth rate (CAGR) of 12.6% from 2023 to 2033. Developments in the detection and treatment of head and neck cancer (HNC) are expected to propel market expansion as they are less costly and more concise to approach than surgeries. The increased prevalence of various types of HNCs, as well as the growing geriatric population, are substantial market drivers.
Moreover, an upsurge in R&D activities involving the development of novel therapeutic objectives and multidisciplinary therapeutic interventions is expected to improve the survival rate of people with head and neck cancers. As the number of people diagnosed with head and neck cancers continues to rise dramatically, there is a significant increase in the demand for novel cancer treatments all over the world. In recent years, there has been a substantial rise in the number of cases of head and neck cancer. According to a World Health Organization (WHO) report, there are over 550,000 cases of head and neck cancer each year, with approximately 300,000 deaths as a consequence of these cancers.
In-Depth Insights, Sample Report Copy! https://www.futuremarketinsights.com/reports/sample/rep-gb-16456
In 2021, North America led the market. Among the key factors that influence regional market expansion is government assistance for medical industry advancement, favorable reimbursement policies, higher disease awareness, increased R&D activities, and easy access to high-quality healthcare facilities.
Key Takeaways from the Market Study:
- North America dominated the market in 2021, accounting for roughly 45% of total revenue.
- Head and neck cancer accounts for approximately 4% of all cancers in the United States.
- China is a significant source of head and neck cancer, accounting for roughly 10% of all systemic malignant cancers each year.
- The retail and specialty pharmacies segment dominated the market in 2021, accounting for 58% of total revenue
- The global Head and Neck Cancer (HNC) Therapeutics market is expected to be worth $5.19 billion by 2033.
“The rapidly expanding pharmaceutical sector and rising penetration of online stores are the major factors expected to drive market growth during the forecast period. Furthermore, numerous development approaches such as collaborations, product launches, and adaptation of cutting-edge technologies have a positive impact on the market and drive overall growth” says FMI analyst.
In Case Of Any Queries, Don’t Hesitate To Contact Our Analyst! https://www.futuremarketinsights.com/ask-question/rep-gb-16456
Key Market Players:
Key players in the head and neck cancer (HNC) therapeutics market are Eli Lilly and Company, Sanofi, Merck & Co., Inc., Clinigen Group plc., Bristol-Myers Squibb Company, AstraZeneca, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, Hoffmann-La Roche Ltd., Coherus BioSciences.
- In December 2021, Sanofi paid USD 1 billion to acquire Amunix Pharmaceuticals, Inc. This acquisition broadens the corporation’s oncology product portfolio and provides significant growth potential.
- In October 2021, the US Food and Drug Administration (FDA) approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy, with or without bevacizumab. Keytruda, a product of Merck & Co., Inc., is given intravenously as an infusion to individuals with head and neck cancer.
Key Segments Profiled in the Head and Neck Cancer (HNC) Therapeutics Market Industry Survey
By Therapy Type:
- Chemotherapy
- Immunotherapy
- Targeted Therapy
By Route of Administration:
- Injectable
- Oral
- By Channel
Retail & Specialty Pharmacies:
- Hospital Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa (MEA)
Ignite Innovation with Customization: Uncover the Possibilities in Our Report! https://www.futuremarketinsights.com/customization-available/rep-gb-16456
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
